Company Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology.
The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6.
It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer.
The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019.
Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
| Country | United States |
| IPO Date | Aug 26, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 203 |
| CEO | Dr. David T. Hung M.D. |
Contact Details
Address: 1500 Broadway New York, New York United States | |
| Website | https://www.nuvationbio.com |
Stock Details
| Ticker Symbol | NUVB |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001811063 |
| CUSIP Number | 67080N101 |
| ISIN Number | US67080N1019 |
| Employer ID | 85-0862255 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David T. Hung M.D. | Founder, President, Chief Executive Officer & Chairman |
| Philippe Sauvage | Chief Financial Officer & Principal Financial Officer |
| Stacy Markel | Chief People Officer |
| Colleen Sjogren | Chief Commercial Officer |
| Dr. David Liu M.D., Ph.D. | Chief Medical Officer |
| Dr. David C. Hanley Ph.D. | Chief Technical Operations Officer |
| Dr. Gary Hattersley Ph.D. | Chief Scientific Officer |
| Kerry A. Wentworth | Chief Regulatory Officer |
| Moses Makunje CPA | Vice President of Finance and Principal Accounting & Financial Officer |
| Stephen Dang | Vice President of Legal & Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 06, 2024 | SCHEDULE 13G/A | [Amend] Filing |
| Nov 13, 2024 | 4 | Filing |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 06, 2024 | 8-K | Current Report |
| Nov 06, 2024 | 10-Q | Quarterly Report |
| Oct 18, 2024 | SC 13D/A | [Amend] Filing |
| Oct 10, 2024 | 4 | Filing |
| Oct 09, 2024 | 4 | Filing |
| Oct 09, 2024 | 3 | Filing |
| Sep 10, 2024 | SC 13D | Filing |